Literature DB >> 29067630

Pulmonary Aspergillus Overlap Syndromes.

Liyang Li1, Zhilong Jiang1, Changzhou Shao2.   

Abstract

BACKGROUND: Broadly, there are three main categories in pulmonary aspergillosis: chronic forms of aspergillosis; allergic bronchopulmonary aspergillosis; and invasive aspergillosis (IPA). IPA has been further subdivided into angioinvasive and airway-invasive aspergillosis. Aspergillus overlap syndromes is defined as the occurrence of more than one form aspergillus disease in a single individual.
OBJECTIVES: To help clinicians correctly deal with AOS.
METHODS: Retrospectively study the clinical findings of nine patients presenting with AOS.
RESULTS: Four cases were diagnosed as angioinvasive aspergillosis complicated with ABPA, three cases as IPA overlap aspergilloma, and two cases as ABPA with AWIA. All the patients presented with cough and expectoration. In three patients with IPA overlap aspergilloma, two had hemoptysis, two had wheezing and fever. All of patients with IPA overlap ABPA had wheezing, dyspnea, and fever, three had sputum plugs, two had hemoptysis, and five patients had mucopurulent discharge and rhonchi in auscultation. Their total IgE ranged from 129 to 2124 IU/ml (676.5 ± 557.33 IU/ml). Fungal culture in sputum showed A. Fumigatus in three patients. All the six patients with IPA overlap ABPA applied steroid therapy and antifungal therapy. Three of them received two or more antifungal drugs successively, and three received combinational therapy. All the patients improved except one diagnosed ABPA overlap IPA.
CONCLUSIONS: Clinical manifestation of AOS is not typical. Poor first-line therapeutic effects and complicated diagnosis criteria require clinicians to be aware of AOS when facing patients with aspergillosis.

Entities:  

Keywords:  Allergic bronchopulmonary aspergillosis; Aspergilloma; Aspergillus overlap syndromes; Invasive pulmonary aspergillosis

Mesh:

Substances:

Year:  2017        PMID: 29067630     DOI: 10.1007/s11046-017-0212-y

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  28 in total

1.  Association of pulmonary aspergilloma and allergic bronchopulmonary aspergillosis.

Authors:  D Montani; I Zendah; L Achouh; P Dorfmuller; O Mercier; G Garcia; M Humbert
Journal:  Eur Respir Rev       Date:  2010-12

2.  High-attenuation mucus in allergic bronchopulmonary aspergillosis: another cause of diffuse high-attenuation pulmonary abnormality.

Authors:  Ritesh Agarwal; Ashutosh N Aggarwal; Dheeraj Gupta
Journal:  AJR Am J Roentgenol       Date:  2006-03       Impact factor: 3.959

3.  Advances against aspergillosis: biology, host response, diagnosis and treatment.

Authors:  David S Askew; Dimitrios P Kontoyiannis; Karl V Clemons
Journal:  Mycopathologia       Date:  2014-10-07       Impact factor: 2.574

Review 4.  Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria.

Authors:  R Agarwal; A Chakrabarti; A Shah; D Gupta; J F Meis; R Guleria; R Moss; D W Denning
Journal:  Clin Exp Allergy       Date:  2013-08       Impact factor: 5.018

5.  Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.

Authors:  Issam I Raad; Aline El Zakhem; Gilbert El Helou; Ying Jiang; Dimitrios P Kontoyiannis; Ray Hachem
Journal:  Int J Antimicrob Agents       Date:  2014-10-12       Impact factor: 5.283

6.  Allergic bronchopulmonary aspergillosis with aspergilloma: an immunologically severe disease with poor outcome.

Authors:  Ritesh Agarwal; Ashutosh N Aggarwal; Mandeep Garg; Biman Saikia; Dheeraj Gupta; Arunaloke Chakrabarti
Journal:  Mycopathologia       Date:  2012-03-29       Impact factor: 2.574

7.  Combination Antifungal Therapy for Invasive Aspergillosis Revisited.

Authors:  Anil A Panackal
Journal:  Med Mycol Open Access       Date:  2016-04-29

Review 8.  Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient.

Authors:  José Garnacho-Montero; Pedro Olaechea; Francisco Alvarez-Lerma; Luis Alvarez-Rocha; José Blanquer; Beatriz Galván; Alejandro Rodriguez; Rafael Zaragoza; José-María Aguado; José Mensa; Amparo Solé; José Barberán
Journal:  Rev Esp Quimioter       Date:  2013-06       Impact factor: 1.553

9.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

Review 10.  Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis.

Authors:  Anil A Panackal; Emilio Parisini; Michael Proschan
Journal:  Int J Infect Dis       Date:  2014-09-18       Impact factor: 3.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.